stockrow
Friday 6 November 2026
Export AXGN’s income statement to Excel — free account
AxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
50.00
1.25
+2.56%
Follow AXGN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 5 | 5 |
+8 more TTM periods Free account |
| (10.35%) | (18.21%) | (17.96%) | (13.49%) | ||
| (8.33%) | (13.15%) | (12.95%) | (7.38%) | ||
ROIC |
(5.27%) | (4.99%) | (3.48%) | (3.25%) | |
Return on Tangible Assets |
(6.60%) | (13.29%) | (13.01%) | (8.79%) | |
Average Days of Receivables |
46.50 | 49.59 | 43.40 | 42.41 | |
Free Cash Flow per Share |
0.36 | 0.12 | 0.15 | (0.10) | |
Free Cash Flow |
20.02 | 6.51 | 7.66 | (4.78) | |
Capital Expenditures |
(8.34) | (8.54) | (7.90) | (5.59) | |
| Other line items | |||||
Cash ROIC |
2.32% | 1.68% | 2.08% | (1.98%) | |
Accounts Receivable Turnover |
8.24 | 8.08 | 8.72 | 8.96 | |
Accounts Payable Turnover |
2.29 | 2.50 | 2.73 | 2.32 | |
Inventory Turnover |
1.54 | 1.52 | 1.46 | 1.53 | |
Average Days of Payables |
183.37 | 162.19 | 146.61 | 133.65 | |
Days of Inventory on Hand |
259.83 | 270.22 | 282.66 | 267.33 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
14.02% | 14.35% | 14.41% | 14.60% | |
Selling, General and Administrative Expense of Revenue |
65.33% | 65.32% | 64.39% | 63.19% | |
Share Based Compensation of Revenue |
15.37% | 14.99% | 14.30% | 13.37% | |
Interest Coverage |
(5.72) | (3.08) | (1.47) | (1.02) | |
Operating CF/Net income |
(0.89) | (0.45) | (0.49) | (0.05) | |
Depreciation/Fixed assets |
0.12 | 0.12 | 0.11 | 0.11 | |
Capex/Depreciation |
(0.86) | (0.89) | (0.83) | (0.60) | |
Revenue per Share |
4.84 | 4.71 | 4.62 | 4.89 | |
Operating CF per Share |
0.51 | 0.28 | 0.30 | 0.02 | |
Capex per Share |
(0.15) | (0.16) | (0.15) | (0.12) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026